Skip to content
10-K

Annual Report

Sunshine Biopharma Inc. SBFM SBFMW

0001683168-25-002184

← back to feed
Filed
Apr 1, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 21, 2025 2.71M sh
Shares Diluted FY 2024 · Dec 31, 2024 701.75K sh
Shares Diluted restated FY 2024 · Dec 31, 2023 12.83K sh
Eps Diluted FY 2024 · Dec 31, 2024 −$7.32
Eps Diluted restated FY 2024 · Dec 31, 2023 −$351.36
Stock Repurchased FY 2024 · Dec 31, 2023 $541.14K
Capex FY 2024 · Dec 31, 2023 $82.25K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$8.78M
Current Liabilities FY 2024 · Dec 31, 2023 $5.55M
Total Liabilities FY 2024 · Dec 31, 2023 $6.14M
Current Assets FY 2024 · Dec 31, 2023 $24.89M
Total Assets FY 2024 · Dec 31, 2023 $27.35M
Eps Basic restated FY 2024 · Dec 31, 2023 −$351.36
Sga Expense FY 2024 · Dec 31, 2023 $13.12M
Rd Expense FY 2024 · Dec 31, 2023 $1.86M
Net Income FY 2024 · Dec 31, 2023 −$4.51M
Operating Income FY 2024 · Dec 31, 2023 −$4.79M
Gross Profit FY 2024 · Dec 31, 2023 $8.34M
Cost Of Revenue FY 2024 · Dec 31, 2023 $15.75M
Revenue FY 2024 · Dec 31, 2023 $24.09M
Stockholders Equity FY 2024 · Dec 31, 2022 $21.63M